drugset / Trial / NCT07230418

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes

NCT07230418 ↗

Phase 1 Completed 82 enrolled Chengdu Suncadia Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS-3095 oral administration in healthy subjects. This study will also explore food effect and the effect of HRS-3095 on CYP3A4 metabolic enzymes.

Timeline

Start
2025-11-10
Primary completion
2026-04-19
Completion
2026-04-19

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-3095 Unknown — Oral